<!DOCTYPE html><html lang="en" ><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><meta name="theme-color" media="(prefers-color-scheme: light)" content="#f7f7f7"><meta name="theme-color" media="(prefers-color-scheme: dark)" content="#1b1b1e"><meta name="apple-mobile-web-app-capable" content="yes"><meta name="apple-mobile-web-app-status-bar-style" content="black-translucent"><meta name="viewport" content="width=device-width, user-scalable=no initial-scale=1, shrink-to-fit=no, viewport-fit=cover" ><meta name="generator" content="Jekyll v4.3.2" /><meta property="og:title" content="Does Enhancement or Perfusion on Preprocedure CT Predict Outcomes After Embolization of Hepatocellular Carcinoma?" /><meta property="og:locale" content="en" /><meta name="description" content="Rationale and Objective" /><meta property="og:description" content="Rationale and Objective" /><link rel="canonical" href="https://clinicaltree.github.io/posts/does-enhancement-or-perfusion-on-preprocedure-ct-predict-outcomes-after-embolization-of-hepatocellul/" /><meta property="og:url" content="https://clinicaltree.github.io/posts/does-enhancement-or-perfusion-on-preprocedure-ct-predict-outcomes-after-embolization-of-hepatocellul/" /><meta property="og:site_name" content="Radiology Tree" /><meta property="og:type" content="article" /><meta property="article:published_time" content="2018-11-30T17:00:00+00:00" /><meta name="twitter:card" content="summary" /><meta property="twitter:title" content="Does Enhancement or Perfusion on Preprocedure CT Predict Outcomes After Embolization of Hepatocellular Carcinoma?" /><meta name="twitter:site" content="@twitter_username" /><meta name="google-site-verification" content="RFHVRgQqK0eGjftEMCTDhsDrR8cJ_ZYcfCX52gXW8KM" /> <script type="application/ld+json"> {"@context":"https://schema.org","@type":"BlogPosting","dateModified":"2023-04-10T03:59:08+00:00","datePublished":"2018-11-30T17:00:00+00:00","description":"Rationale and Objective","headline":"Does Enhancement or Perfusion on Preprocedure CT Predict Outcomes After Embolization of Hepatocellular Carcinoma?","mainEntityOfPage":{"@type":"WebPage","@id":"https://clinicaltree.github.io/posts/does-enhancement-or-perfusion-on-preprocedure-ct-predict-outcomes-after-embolization-of-hepatocellul/"},"url":"https://clinicaltree.github.io/posts/does-enhancement-or-perfusion-on-preprocedure-ct-predict-outcomes-after-embolization-of-hepatocellul/"}</script><title>Does Enhancement or Perfusion on Preprocedure CT Predict Outcomes After Embolization of Hepatocellular Carcinoma? | Radiology Tree</title><link rel="apple-touch-icon" sizes="180x180" href="/assets/img/favicons/apple-touch-icon.png"><link rel="icon" type="image/png" sizes="32x32" href="/assets/img/favicons/favicon-32x32.png"><link rel="icon" type="image/png" sizes="16x16" href="/assets/img/favicons/favicon-16x16.png"><link rel="manifest" href="/assets/img/favicons/site.webmanifest"><link rel="shortcut icon" href="/assets/img/favicons/favicon.ico"><meta name="apple-mobile-web-app-title" content="Radiology Tree"><meta name="application-name" content="Radiology Tree"><meta name="msapplication-TileColor" content="#da532c"><meta name="msapplication-config" content="/assets/img/favicons/browserconfig.xml"><meta name="theme-color" content="#ffffff"><link rel="preconnect" href="https://fonts.googleapis.com" ><link rel="dns-prefetch" href="https://fonts.googleapis.com" ><link rel="preconnect" href="https://fonts.gstatic.com" crossorigin><link rel="dns-prefetch" href="https://fonts.gstatic.com" crossorigin><link rel="preconnect" href="https://fonts.googleapis.com" ><link rel="dns-prefetch" href="https://fonts.googleapis.com" ><link rel="preconnect" href="https://cdn.jsdelivr.net" ><link rel="dns-prefetch" href="https://cdn.jsdelivr.net" ><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Lato&family=Source+Sans+Pro:wght@400;600;700;900&display=swap"><link rel="preconnect" href="https://www.google-analytics.com" crossorigin="use-credentials"><link rel="dns-prefetch" href="https://www.google-analytics.com"><link rel="preconnect" href="https://www.googletagmanager.com" crossorigin="anonymous"><link rel="dns-prefetch" href="https://www.googletagmanager.com"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/bootstrap@4.6.2/dist/css/bootstrap.min.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/@fortawesome/fontawesome-free@6.2.1/css/all.min.css"><link rel="stylesheet" href="/assets/css/style.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/tocbot@4.20.1/dist/tocbot.min.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/magnific-popup@1.1.0/dist/magnific-popup.min.css"> <script src="https://cdn.jsdelivr.net/npm/jquery@3.6.1/dist/jquery.min.js"></script> <script type="text/javascript"> class ModeToggle { static get MODE_KEY() { return "mode"; } static get MODE_ATTR() { return "data-mode"; } static get DARK_MODE() { return "dark"; } static get LIGHT_MODE() { return "light"; } static get ID() { return "mode-toggle"; } constructor() { if (this.hasMode) { if (this.isDarkMode) { if (!this.isSysDarkPrefer) { this.setDark(); } } else { if (this.isSysDarkPrefer) { this.setLight(); } } } let self = this; /* always follow the system prefers */ this.sysDarkPrefers.addEventListener('change', () => { if (self.hasMode) { if (self.isDarkMode) { if (!self.isSysDarkPrefer) { self.setDark(); } } else { if (self.isSysDarkPrefer) { self.setLight(); } } self.clearMode(); } self.notify(); }); } /* constructor() */ get sysDarkPrefers() { return window.matchMedia("(prefers-color-scheme: dark)"); } get isSysDarkPrefer() { return this.sysDarkPrefers.matches; } get isDarkMode() { return this.mode === ModeToggle.DARK_MODE; } get isLightMode() { return this.mode === ModeToggle.LIGHT_MODE; } get hasMode() { return this.mode != null; } get mode() { return sessionStorage.getItem(ModeToggle.MODE_KEY); } /* get the current mode on screen */ get modeStatus() { if (this.isDarkMode || (!this.hasMode && this.isSysDarkPrefer)) { return ModeToggle.DARK_MODE; } else { return ModeToggle.LIGHT_MODE; } } setDark() { $('html').attr(ModeToggle.MODE_ATTR, ModeToggle.DARK_MODE); sessionStorage.setItem(ModeToggle.MODE_KEY, ModeToggle.DARK_MODE); } setLight() { $('html').attr(ModeToggle.MODE_ATTR, ModeToggle.LIGHT_MODE); sessionStorage.setItem(ModeToggle.MODE_KEY, ModeToggle.LIGHT_MODE); } clearMode() { $('html').removeAttr(ModeToggle.MODE_ATTR); sessionStorage.removeItem(ModeToggle.MODE_KEY); } /* Notify another plugins that the theme mode has changed */ notify() { window.postMessage({ direction: ModeToggle.ID, message: this.modeStatus }, "*"); } flipMode() { if (this.hasMode) { if (this.isSysDarkPrefer) { if (this.isLightMode) { this.clearMode(); } else { this.setLight(); } } else { if (this.isDarkMode) { this.clearMode(); } else { this.setDark(); } } } else { if (this.isSysDarkPrefer) { this.setLight(); } else { this.setDark(); } } this.notify(); } /* flipMode() */ } /* ModeToggle */ const modeToggle = new ModeToggle(); </script><body data-topbar-visible="true"><div id="sidebar" class="d-flex flex-column align-items-end"><div class="profile-wrapper text-center"><div id="avatar"> <a href="/" class="mx-auto"> <img src="https://storage.googleapis.com/clinicalpub.com/images/favicon.png" alt="avatar" onerror="this.style.display='none'"> </a></div><div class="site-title"> <a href="/">Radiology Tree</a></div><div class="site-subtitle font-italic">Update every day the best and the lastest articles, books, journals, clinical cases, videos, images... for radiologist</div></div><ul class="w-100"><li class="nav-item"> <a href="/" class="nav-link"> <i class="fa-fw fas fa-home ml-xl-3 mr-xl-3 unloaded"></i> <span>HOME</span> </a><li class="nav-item"> <a href="/categories/" class="nav-link"> <i class="fa-fw fas fa-stream ml-xl-3 mr-xl-3 unloaded"></i> <span>CATEGORIES</span> </a><li class="nav-item"> <a href="/tags/" class="nav-link"> <i class="fa-fw fas fa-tag ml-xl-3 mr-xl-3 unloaded"></i> <span>TAGS</span> </a><li class="nav-item"> <a href="/archives/" class="nav-link"> <i class="fa-fw fas fa-archive ml-xl-3 mr-xl-3 unloaded"></i> <span>ARCHIVES</span> </a><li class="nav-item"> <a href="/about/" class="nav-link"> <i class="fa-fw fas fa-info-circle ml-xl-3 mr-xl-3 unloaded"></i> <span>ABOUT</span> </a></ul><div class="sidebar-bottom mt-auto d-flex flex-wrap justify-content-center align-items-center"> <button class="mode-toggle btn" aria-label="Switch Mode"> <i class="fas fa-adjust"></i> </button> <span class="icon-border"></span> <a href="https://github.com/clinicaltree" aria-label="github" target="_blank" rel="noopener noreferrer"> <i class="fab fa-github"></i> </a> <a href="https://twitter.com/twitter_username" aria-label="twitter" target="_blank" rel="noopener noreferrer"> <i class="fab fa-twitter"></i> </a> <a href="javascript:location.href = 'mailto:' + ['clinicalpub.team','gmail.com'].join('@')" aria-label="email" > <i class="fas fa-envelope"></i> </a> <a href="/feed.xml" aria-label="rss" > <i class="fas fa-rss"></i> </a></div></div><div id="topbar-wrapper"><div id="topbar" class="container d-flex align-items-center justify-content-between h-100 pl-3 pr-3 pl-md-4 pr-md-4"> <span id="breadcrumb"> <span> <a href="/"> Home </a> </span> <span>Does Enhancement or Perfusion on Preprocedure CT Predict Outcomes After Embolization of Hepatocellular Carcinoma?</span> </span> <i id="sidebar-trigger" class="fas fa-bars fa-fw"></i><div id="topbar-title"> Post</div><i id="search-trigger" class="fas fa-search fa-fw"></i> <span id="search-wrapper" class="align-items-center"> <i class="fas fa-search fa-fw"></i> <input class="form-control" id="search-input" type="search" aria-label="search" autocomplete="off" placeholder="Search..."> </span> <span id="search-cancel" >Cancel</span></div></div><div id="main-wrapper" class="d-flex justify-content-center"><div id="main" class="container pl-xl-4 pr-xl-4"><div class="row"><div id="core-wrapper" class="col-12 col-lg-11 col-xl-9 pr-xl-4"><div class="post pl-1 pr-1 pl-md-2 pr-md-2"><h1 data-toc-skip>Does Enhancement or Perfusion on Preprocedure CT Predict Outcomes After Embolization of Hepatocellular Carcinoma?</h1><div class="post-meta text-muted"> <span> Posted <em class="" data-ts="1543597200" data-df="ll" data-toggle="tooltip" data-placement="bottom"> Nov 30, 2018 </em> </span> <span> Updated <em class="" data-ts="1681099148" data-df="ll" data-toggle="tooltip" data-placement="bottom"> Apr 10, 2023 </em> </span><div class="d-flex justify-content-between"> <span> By <em> <a href="">Alessra Borgheresi MD</a> </em>, <em> <a href="">Adrian Gonzalez-Aguirre MD</a> </em>, <em> <a href="">Karen T. Brown MD</a> </em>, <em> <a href="">George I. Getrajdman MD</a> </em>, <em> <a href="">Joseph P. Erinjeri MD PhD</a> </em>, <em> <a href="">Anne Covey MD</a> </em>, <em> <a href="">Hooman Yarmohammadi MD</a> </em>, <em> <a href="">Etay Ziv MD PhD</a> </em>, <em> <a href="">Constantinos T. Sofocleous MD PhD</a> </em>, <em> <a href="">Franz Edward Boas MD PhD</a> </em> </span><div> <span class="readtime" data-toggle="tooltip" data-placement="bottom" title="1826 words"> <em>10 min</em> read</span></div></div></div><div class="post-content"><h2 id="rationale-and-objective"><span class="mr-2">Rationale and Objective</span><a href="#rationale-and-objective" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>The objective of this study was to evaluate whether quantitative enhancement or perfusion measurements on preprocedure triphasic computed tomography (CT) can be used to predict response or overall survival after embolization of hepatocellular carcinoma.</p><h2 id="materials-and-methods"><span class="mr-2">Materials and Methods</span><a href="#materials-and-methods" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>The institutional review board approved this retrospective review of 63 patients with hepatocellular carcinoma treated with particle embolization between March 2009 and December 2014. Quantitative enhancement and perfusion measurements were performed on the target tumor and the background liver on the triphasic CT performed before treatment. Microvascular invasion (MVI) and degree of differentiation were determined from a core biopsy specimen. Quantitative enhancement and perfusion values were then correlated with pathology (two-tailed <em>t</em> test), response to embolization on modified Response Evaluation Criteria In Solid Tumors (two-tailed <em>t</em> test), and overall survival after embolization (Cox proportional hazards model).</p><h2 id="results"><span class="mr-2">Results</span><a href="#results" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>Arterial enhancement did not predict immediate response or overall survival after embolization. The degree of differentiation or presence of MVI also did not predict immediate response or overall survival after embolization. However, high hepatic artery coefficient or low portal vein coefficient, both in the tumor ( <em>P</em> = .011 and <em>P</em> = .004) and in the background liver ( <em>P</em> = .015 and <em>P</em> = .009), were associated with worse survival. Hepatic artery coefficient, both in the tumor ( <em>P</em> = .025) and in the background liver ( <em>P</em> = .013), were independent predictors of survival in a multivariate model including the Child-Pugh score and the BCLC stage.</p><h2 id="conclusions"><span class="mr-2">Conclusions</span><a href="#conclusions" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>Tumor and liver perfusion parameters estimated from preprocedure triphasic CT were predictive of survival after embolization. Arterial-phase enhancement and histology (degree of differentiation or MVI) did not predict immediate response or overall survival after particle embolization.</p><h2 id="introduction"><span class="mr-2">Introduction</span><a href="#introduction" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>Treatment options for unresectable and unablatable hepatocellular carcinoma (HCC) include transarterial embolization (TAE), transarterial chemoembolization (TACE) using either lipiodol or drug-eluting beads, radioembolization, and sorafenib. Recent randomized trials have shown no difference in overall survival for these treatment options, although there are differences in response rates and quality of life .</p><p>Regardless of the treatment, there are a subset of patients who do not respond . Although overall survival after the various different treatment options for unresectable HCC appears to be similar, there might be subgroups that do better with one treatment compared to another . Predicting which patients will have poor outcomes with one treatment option could potentially allow these patients to be directed to a different treatment option.</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="materials-and-methods-1"><span class="mr-2">Materials and Methods</span><a href="#materials-and-methods-1" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><h2 id="patient-selection"><span class="mr-2">Patient Selection</span><a href="#patient-selection" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="transarterial-embolization"><span class="mr-2">Transarterial Embolization</span><a href="#transarterial-embolization" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="imaging-protocol"><span class="mr-2">Imaging Protocol</span><a href="#imaging-protocol" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="image-evaluation"><span class="mr-2">Image Evaluation</span><a href="#image-evaluation" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="statistical-analysis"><span class="mr-2">Statistical Analysis</span><a href="#statistical-analysis" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="results-1"><span class="mr-2">Results</span><a href="#results-1" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><h2 id="patient-characteristics"><span class="mr-2">Patient Characteristics</span><a href="#patient-characteristics" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>TABLE 1</p><p>Patient Characteristics</p><p><em>n</em> (%) Child-Pugh score A 58 (92) B 5 (8) C 0 (0) BCLC stage 0 1 (1) A 18 (29) B 34 (54) C 10 (16) Etiology of liver disease HBV 10 (16) HCV 18 (29) Alcoholism 6 (10) NASH 5 (8) Other 18 (29) Multiple 5 (8) Cirrhosis Yes 37 (59) No 26 (41) Pathology (degree of differentiation) Well differentiated 12 (19) Moderately differentiated 26 (41) Poorly differentiated 6 (10) Undifferentiated 0 (0) Fibrolamellar 2 (3) Not specified 8 (13) Core biopsy not performed 9 (14) Pathology (MVI) Yes 9 (14) No 45 (71) Core biopsy not performed 9 (14)</p><p>BCLC, Barcelona Clinic Liver Cancer; HBV, hepatitis B virus; HCV, hepatitis C virus; MVI, microvascular invasion; NASH, nonalcoholic steatohepatitis.</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="predicting-response-to-embolization"><span class="mr-2">Predicting Response to Embolization</span><a href="#predicting-response-to-embolization" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>TABLE 2</p><p>Hepatocellular Carcinoma Enhancement, Perfusion Parameters, and Pathology Did Not Predict CR After Embolization</p><p>CR (Av. ± SD) Non-CR (Av. ± SD)<em>P</em> Value HAC 0.03 ± 0.22 0.08 ± 0.29 .45 PVC 0.44 ± 0.27 0.31 ± 0.41 .14 AEF 0.74 ± 0.25 0.94 ± 0.83 .21 Arterial-phase enhancement (HU) 44 ± 17 45 ± 36 .86 Portal venous-phase enhancement (HU) 60 ± 15 53 ± 20 .13 Moderate to poorly differentiated 12/16 20/28 1.0 MVI 5/25 4/29 .72</p><p>AEF, arterial enhancement fraction; Av., average; CR, complete response; HAC, hepatic artery coefficient; MVI, microvascular invasion; PVC, portal vein coefficient; SD, standard deviation.</p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/DoesEnhancementorPerfusiononPreprocedureCTPredictOutcomesAfterEmbolizationofHepatocellularCarcinoma/0_1s20S1076633218301181.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/DoesEnhancementorPerfusiononPreprocedureCTPredictOutcomesAfterEmbolizationofHepatocellularCarcinoma/0_1s20S1076633218301181.jpg" alt="Figure 1, Tumor arterial enhancement did not predict response to embolization or overall survival. Examples show that hypervascular HCC can fail to respond to embolization, and hypovascular HCC can respond to embolization. (a) HCC of a 67-year-old man appears hypervascular on arterial-phase computed tomography. (b) This tumor progressed after embolization. (c) HCC of a 62-year-old man appears hypovascular on arterial-phase computed tomography. (d) This tumor appears necrotic after embolization. HCC, hepatocellular carcinoma." class="lazyload" data-proofer-ignore></a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="predicting-overall-survival-after-embolization"><span class="mr-2">Predicting Overall Survival After Embolization</span><a href="#predicting-overall-survival-after-embolization" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>TABLE 3</p><p>Predictors of Overall Survival After Embolization of Hepatocellular Carcinoma (Cox Proportional Hazards Model)</p><p>Univariate Model</p><p>Relative Risk ( <em>P</em> Value) Multivariate Model</p><p>Relative Risk ( <em>P</em> Value) Tumor HAC 3.85 (.011 \* ) 4.38 (.025 \* ) PVC 0.32 (.004 \* ) AEF 1.39 (.115) Arterial-phase enhancement (HU) 1 (.73) PV-phase enhancement (HU) 0.99 (.28) Liver HAC 1.27 (.015 \* ) 1.33 (.013 \* ) PVC 0.75 (.009 \* ) Child-Pugh score 1.04 (.83) 1.08 (.684) BCLC stage 0 or A 0.69 (.34) 1 (n/a) B 0.55 (.084) 0.86 (.725) C 6.77 (2.9 × 10 −6 \* ) 6.31 (.00016 \* )</p><p>AEF, arterial enhancement fraction; BCLC, Barcelona Clinic Liver Cancer; HAC, hepatic artery coefficient; n/a, not applicable; PV, portal venous; PVC, portal vein coefficient.</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/DoesEnhancementorPerfusiononPreprocedureCTPredictOutcomesAfterEmbolizationofHepatocellularCarcinoma/1_1s20S1076633218301181.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/DoesEnhancementorPerfusiononPreprocedureCTPredictOutcomesAfterEmbolizationofHepatocellularCarcinoma/1_1s20S1076633218301181.jpg" alt="Figure 2, Perfusion parameters in both the HCC and the background liver are independent predictors of overall survival (see Table 3 for P values). (a) Red : tumor HAC ≤−0.07, blue : tumor HAC &gt;−0.07. (b) Red : liver HAC ≤−0.21, blue : liver HAC &gt;−0.21. HAC, hepatic artery coefficient; HCC, hepatocellular carcinoma. (Color version of figure is available online.)" class="lazyload" data-proofer-ignore></a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/DoesEnhancementorPerfusiononPreprocedureCTPredictOutcomesAfterEmbolizationofHepatocellularCarcinoma/2_1s20S1076633218301181.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/DoesEnhancementorPerfusiononPreprocedureCTPredictOutcomesAfterEmbolizationofHepatocellularCarcinoma/2_1s20S1076633218301181.jpg" alt="Figure 3, Histology (microvascular invasion and degree of differentiation from a core biopsy) did not predict overall survival after embolization. (a) Red : no microvascular invasion, blue : microvascular invasion ( P = .45). (b) Red : well-differentiated HCC, blue : moderate or poorly differentiated HCC ( P = .87). HCC, hepatocellular carcinoma; MVI, microvascular invasion. (Color version of figure is available online.)" class="lazyload" data-proofer-ignore></a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="predicting-pathology-from-imaging"><span class="mr-2">Predicting Pathology From Imaging</span><a href="#predicting-pathology-from-imaging" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>TABLE 4</p><p>Higher Arterial or Portal Venous-phase Enhancement Predicts Moderate to Poorly Differentiated Hepatocellular Carcinoma</p><p>Well-differentiated (Av. ± SD) Moderately to Poorly Differentiated (Av. ± SD)<em>P</em> Value Arterial-phase enhancement (HU) 29 ± 16 52 ± 52 .004 \* PV-phase enhancement (HU) 43 ± 19 58 ± 58 .028 \* HAC 0.02 ± 0.19 0.10 ± 0.10 .345 PVC 0.27 ± 0.34 0.37 ± 0.37 .415 AEF 0.94 ± 0.99 0.91 ± 0.91 .922</p><p>AEF, arterial enhancement fraction; Av., average; HAC, hepatic artery coefficient; PV, portal venous; PVC, portal vein coefficient; SD, standard deviation.</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="discussion"><span class="mr-2">Discussion</span><a href="#discussion" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="supplementary-data"><span class="mr-2">Supplementary Data</span><a href="#supplementary-data" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>Appendix S1</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="references"><span class="mr-2">References</span><a href="#references" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><ul><li><p>1. Salem R., Gordon A.C., Mouli S., et. al.: Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2016; 151: pp. 1155-1163. e2</p><li><p>2. Vilgrain V., Bouattour M., Sibert A., et. al.: SARAH: A randomised controlled trial comparing efficacy and safety of selective internal radiation therapy (with yttrium-90 microspheres) and sorafenib in patients with locally advanced hepatocellular carcinoma. J Hepatol 2017; 66: pp. S85-S86.</p><li><p>3. Brown K.T., Do R.K., Gonen M., et. al.: Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone. J Clin Oncol 2016; 34: pp. 2046-2053.</p><li><p>4. Biederman D.M., Titano J.J., Tabori N.E., et. al.: Outcomes of radioembolization in the treatment of hepatocellular carcinoma with portal vein invasion: resin versus glass microspheres. J Vasc Interv Radiol 2016; 27: pp. 812-821. e2</p><li><p>5. Katyal S., Oliver J.H., Peterson M.S., et. al.: Prognostic significance of arterial phase CT for prediction of response to transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma: a retrospective analysis. AJR Am J Roentgenol 2000; 175: pp. 1665-1672.</p><li><p>6. Hu H.T., Kim J.H., Lee L.S., et. al.: Chemoembolization for hepatocellular carcinoma: multivariate analysis of predicting factors for tumor response and survival in a 362-patient cohort. J Vasc Interv Radiol 2011; 22: pp. 917-923.</p><li><p>7. Artinyan A., Nelson R., Soriano P., et. al.: Treatment response to transcatheter arterial embolization and chemoembolization in primary and metastatic tumors of the liver. HPB (Oxford) 2008; 10: pp. 396-404.</p><li><p>8. Kwan S.W., Fidelman N., Ma E., et. al.: Imaging predictors of the response to transarterial chemoembolization in patients with hepatocellular carcinoma: a radiological-pathological correlation. Liver Transpl 2012; 18: pp. 727-736.</p><li><p>9. Sato K.T., Omary R.A., Takehana C., et. al.: The role of tumor vascularity in predicting survival after yttrium-90 radioembolization for liver metastases. J Vasc Interv Radiol 2009; 20: pp. 1564-1569.</p><li><p>10. Boas F.E., Brody L.A., Erinjeri J.P., et. al.: Quantitative measurements of enhancement on preprocedure triphasic CT can predict response of colorectal liver metastases to radioembolization. AJR Am J Roentgenol 2016; 207: pp. 671-675.</p><li><p>11. Boas F.E., Kamaya A., Do B., et. al.: Classification of hypervascular liver lesions based on hepatic artery and portal vein blood supply coefficients calculated from triphasic CT scans. J Digit Imaging 2015; 28: pp. 213-223.</p><li><p>12. Lencioni R., Llovet J.M.: Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: pp. 52-60.</p><li><p>13. Brown K.T.: Bland embolization for hepatic malignancies.Mauro M.A.Murphy K.P.J.Thomson K.R. et. al.Image-guided interventions.2014.ElsevierPhiladelphia, PA:pp. 467-475.</p><li><p>14. Budczies J., Klauschen F., Sinn B.V., et. al.: Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS ONE 2012; 7: e51862</p><li><p>15. Herber S., Biesterfeld S., Franz U., et. al.: Correlation of multislice CT and histomorphology in HCC following TACE: predictors of outcome. Cardiovasc Intervent Radiol 2008; 31: pp. 768-777.</p><li><p>16. Lim K.C., Chow P.K., Allen J.C., et. al.: Microvascular invasion is a better predictor of tumor recurrence and overall survival following surgical resection for hepatocellular carcinoma compared to the Milan criteria. Ann Surg 2011; 254: pp. 108-113.</p><li><p>17. Jonas S., Bechstein W.O., Steinmuller T., et. al.: Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001; 33: pp. 1080-1086.</p><li><p>18. Lee E.C., Kim S.H., Park H., et. al.: Survival analysis after liver resection for hepatocellular carcinoma: a consecutive cohort of 1002 patients. J Gastroenterol Hepatol 2017; 32: pp. 1055-1063.</p><li><p>19. Choi J.Y., Lee J.M., Sirlin C.B.: CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects. Radiology 2014; 272: pp. 635-654.</p><li><p>20. Kitao A., Zen Y., Matsui O., et. al.: Hepatocarcinogenesis: multistep changes of drainage vessels at CT during arterial portography and hepatic arteriography—radiologic-pathologic correlation. Radiology 2009; 252: pp. 605-614.</p><li><p>21. Gulberg V., Haag K., Rossle M., et. al.: Hepatic arterial buffer response in patients with advanced cirrhosis. Hepatology 2002; 35: pp. 630-634.</p></ul></div><div class="post-tail-wrapper text-muted"><div class="post-meta mb-3"> <i class="far fa-folder-open fa-fw mr-1"></i> <a href='/categories/academic-radiology/'>Academic Radiology</a>, <a href='/categories/volume-25/'>Volume 25</a>, <a href='/categories/issue-12/'>Issue 12</a></div><div class="post-tags"> <i class="fa fa-tags fa-fw mr-1"></i> <a href="/tags/journals/" class="post-tag no-text-decoration" >Journals</a> <a href="/tags/general-radiology/" class="post-tag no-text-decoration" >General Radiology</a></div><div class="post-tail-bottom d-flex justify-content-between align-items-center mt-3 pt-5 pb-2"><div class="license-wrapper"> This post is licensed under <a href="https://creativecommons.org/licenses/by/4.0/"> CC BY 4.0 </a> by the author.</div><div class="share-wrapper"> <span class="share-label text-muted mr-1">Share</span> <span class="share-icons"> <a href="https://twitter.com/intent/tweet?text=Does%20Enhancement%20or%20Perfusion%20on%20Preprocedure%20CT%20Predict%20Outcomes%20After%20Embolization%20of%20Hepatocellular%20Carcinoma?%20-%20Radiology%20Tree&url=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fdoes-enhancement-or-perfusion-on-preprocedure-ct-predict-outcomes-after-embolization-of-hepatocellul%2F" data-toggle="tooltip" data-placement="top" title="Twitter" target="_blank" rel="noopener" aria-label="Twitter"> <i class="fa-fw fab fa-twitter"></i> </a> <a href="https://www.facebook.com/sharer/sharer.php?title=Does%20Enhancement%20or%20Perfusion%20on%20Preprocedure%20CT%20Predict%20Outcomes%20After%20Embolization%20of%20Hepatocellular%20Carcinoma?%20-%20Radiology%20Tree&u=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fdoes-enhancement-or-perfusion-on-preprocedure-ct-predict-outcomes-after-embolization-of-hepatocellul%2F" data-toggle="tooltip" data-placement="top" title="Facebook" target="_blank" rel="noopener" aria-label="Facebook"> <i class="fa-fw fab fa-facebook-square"></i> </a> <a href="https://t.me/share/url?url=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fdoes-enhancement-or-perfusion-on-preprocedure-ct-predict-outcomes-after-embolization-of-hepatocellul%2F&text=Does%20Enhancement%20or%20Perfusion%20on%20Preprocedure%20CT%20Predict%20Outcomes%20After%20Embolization%20of%20Hepatocellular%20Carcinoma?%20-%20Radiology%20Tree" data-toggle="tooltip" data-placement="top" title="Telegram" target="_blank" rel="noopener" aria-label="Telegram"> <i class="fa-fw fab fa-telegram"></i> </a> <i id="copy-link" class="fa-fw fas fa-link small" data-toggle="tooltip" data-placement="top" title="Copy link" data-title-succeed="Link copied successfully!"> </i> </span></div></div></div></div></div><div id="panel-wrapper" class="col-xl-3 pl-2 text-muted"><div class="access"><div id="access-lastmod" class="post"><div class="panel-heading">Recently Updated</div><ul class="post-content pl-0 pb-1 ml-1 mt-2"><li><a href="/posts/neurometabolites-alteration-in-the-acute-phase-of-mild-traumatic-brain-injury-mtbi/">Neurometabolites Alteration in the Acute Phase of Mild Traumatic Brain Injury (mTBI)</a><li><a href="/posts/reinforcing-the-importance-and-feasibility-of-implementing-a-low-dose-protocol-for-ct-guided-biopsie/">Reinforcing the Importance and Feasibility of Implementing a Low-dose Protocol for CT-guided Biopsies</a><li><a href="/posts/rethinking-the-pgy-1-basic-clinical-year/">Rethinking the PGY-1 Basic Clinical Year</a><li><a href="/posts/single-injection-dual-phase-cone-beam-ct-dp-cbct-vascular-anatomy-assessment-and-occult-nodule-det/">Single Injection Dual-Phase Cone Beam CT (DP-CBCT) Vascular Anatomy Assessment and Occult Nodule Detection; Have We Reached the Focus?</a><li><a href="/posts/the-yellow-scale-is-superior-to-the-gray-scale-for-detecting-acute-ischemic-stroke-on-a-monitor-disp/">The Yellow Scale Is Superior to the Gray Scale for Detecting Acute Ischemic Stroke on a Monitor Display in Computed Tomography</a></ul></div><div id="access-tags"><div class="panel-heading">Trending Tags</div><div class="d-flex flex-wrap mt-3 mb-1 mr-3"> <a class="post-tag" href="/tags/general-radiology/">General Radiology</a> <a class="post-tag" href="/tags/journals/">Journals</a></div></div></div><div id="toc-wrapper" class="pl-0 pr-4 mb-5"><div class="panel-heading pl-3 pt-2 mb-2">Contents</div><nav id="toc"></nav></div><script src="https://cdn.jsdelivr.net/npm/tocbot@4.20.1/dist/tocbot.min.js"></script></div></div><div class="row"><div id="tail-wrapper" class="col-12 col-lg-11 col-xl-9 pl-3 pr-3 pr-xl-4 mt-5"><div id="related-posts" class="mb-2 mb-sm-4"><h3 class="pt-2 mb-4 ml-1" data-toc-skip>Further Reading</h3><div class="card-deck mb-4"><div class="card"> <a href="/posts/a-radiomics-signature-in-preoperative-predicting-degree-of-tumor-differentiation-in-patients-with-no/"><div class="card-body"> <em class="small" data-ts="1543597200" data-df="ll" > Nov 30, 2018 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>A Radiomics Signature in Preoperative Predicting Degree of Tumor Differentiation in Patients with Non–small Cell Lung Cancer</h3><div class="text-muted small"><p> Rationale and Objectives Poorly differentiated non–small cell lung cancer (NSCLC) indicated a poor prognosis and well-differentiated NSCLC indicates a noninvasive nature and good prognosis. The pu...</p></div></div></a></div><div class="card"> <a href="/posts/accuracy-of-dual-energy-virtual-monochromatic-ct-numbers/"><div class="card-body"> <em class="small" data-ts="1543597200" data-df="ll" > Nov 30, 2018 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>Accuracy of Dual-Energy Virtual Monochromatic CT Numbers</h3><div class="text-muted small"><p> Rationale and Objectives To investigate the accuracy of dual-energy virtual monochromatic computed tomography (CT) numbers obtained by two typical hardware and software implementations: the single...</p></div></div></a></div><div class="card"> <a href="/posts/automated-breast-ultrasound-interpretation-times/"><div class="card-body"> <em class="small" data-ts="1543597200" data-df="ll" > Nov 30, 2018 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>Automated Breast Ultrasound Interpretation Times</h3><div class="text-muted small"><p> Rationale and Objectives This study aimed to determine the average time for breast radiologists of varied experience to interpret automated breast ultrasound (ABUS) examinations. Materials and Me...</p></div></div></a></div></div></div><div class="post-navigation d-flex justify-content-between"> <a href="/posts/determination-of-prostate-volume/" class="btn btn-outline-primary" prompt="Older"><p>Determination of Prostate Volume</p></a> <a href="/posts/enhancement-of-musculoskeletal-radiology-resident-education-with-the-use-of-an-individual-smart-port/" class="btn btn-outline-primary" prompt="Newer"><p>Enhancement of Musculoskeletal Radiology Resident Education with the Use of an Individual Smart Portable Ultrasound Device (iSPUD)</p></a></div></div></div></div><div id="search-result-wrapper" class="d-flex justify-content-center unloaded"><div class="col-12 col-sm-11 post-content"><div id="search-hints"><div id="access-tags"><div class="panel-heading">Trending Tags</div><div class="d-flex flex-wrap mt-3 mb-1 mr-3"> <a class="post-tag" href="/tags/general-radiology/">General Radiology</a> <a class="post-tag" href="/tags/journals/">Journals</a></div></div></div><div id="search-results" class="d-flex flex-wrap justify-content-center text-muted mt-3"></div></div></div></div><footer><div class="container pl-lg-4 pr-lg-4"><div class="d-flex justify-content-between align-items-center text-muted ml-md-3 mr-md-3"><div class="footer-left"><p class="mb-0"> © 2023 <a href="https://twitter.com/username">Clinical Team</a>. <span data-toggle="tooltip" data-placement="top" title="Except where otherwise noted, the blog posts on this site are licensed under the Creative Commons Attribution 4.0 International (CC BY 4.0) License by the author.">Some rights reserved.</span></p></div><div class="footer-right"><p class="mb-0">Using the <a href="https://jekyllrb.com" target="_blank" rel="noopener">Jekyll</a> theme <a href="https://github.com/cotes2020/jekyll-theme-chirpy" target="_blank" rel="noopener">Chirpy</a>.</p></div></div></div></footer><div id="mask"></div><a id="back-to-top" href="#" aria-label="back-to-top" class="btn btn-lg btn-box-shadow" role="button"> <i class="fas fa-angle-up"></i> </a><div id="notification" class="toast" role="alert" aria-live="assertive" aria-atomic="true" data-animation="true" data-autohide="false"><div class="toast-header"> <button type="button" class="ml-2 ml-auto close" data-dismiss="toast" aria-label="Close"> <span aria-hidden="true">&times;</span> </button></div><div class="toast-body text-center pt-0"><p class="pl-2 pr-2 mb-3">A new version of content is available.</p><button type="button" class="btn btn-primary" aria-label="Update"> Update </button></div></div><script src="https://cdn.jsdelivr.net/npm/simple-jekyll-search@1.10.0/dest/simple-jekyll-search.min.js"></script> <script> SimpleJekyllSearch({ searchInput: document.getElementById('search-input'), resultsContainer: document.getElementById('search-results'), json: '/assets/js/data/search.json', searchResultTemplate: '<div class="pl-1 pr-1 pl-sm-2 pr-sm-2 pl-lg-4 pr-lg-4 pl-xl-0 pr-xl-0"> <a href="{url}">{title}</a><div class="post-meta d-flex flex-column flex-sm-row text-muted mt-1 mb-1"> {categories} {tags}</div><p>{snippet}</p></div>', noResultsText: '<p class="mt-5">Oops! No results found.</p>', templateMiddleware: function(prop, value, template) { if (prop === 'categories') { if (value === '') { return `${value}`; } else { return `<div class="mr-sm-4"><i class="far fa-folder fa-fw"></i>${value}</div>`; } } if (prop === 'tags') { if (value === '') { return `${value}`; } else { return `<div><i class="fa fa-tag fa-fw"></i>${value}</div>`; } } } }); </script> <script src="https://cdn.jsdelivr.net/combine/npm/magnific-popup@1.1.0/dist/jquery.magnific-popup.min.js,npm/lazysizes@5.3.2/lazysizes.min.js,npm/clipboard@2.0.11/dist/clipboard.min.js"></script> <script src="https://cdn.jsdelivr.net/combine/npm/dayjs@1.11.6/dayjs.min.js,npm/dayjs@1.11.6/locale/en.min.js,npm/dayjs@1.11.6/plugin/relativeTime.min.js,npm/dayjs@1.11.6/plugin/localizedFormat.min.js"></script> <script defer src="/assets/js/dist/post.min.js"></script> <script src="https://cdn.jsdelivr.net/npm/bootstrap@4.6.2/dist/js/bootstrap.bundle.min.js"></script> <script defer src="/app.js"></script> <script defer src="https://www.googletagmanager.com/gtag/js?id=G-L66SLQK23K"></script> <script> document.addEventListener("DOMContentLoaded", function(event) { window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-L66SLQK23K'); }); </script>
